STOK
Neutral signalScored 2026-08-26 Drivers: fundamentals. Moteurs : fondamentaux.
Research, not advice.
À propos
Stoke Therapeutics, Inc.
- Nom
- Stoke Therapeutics, Inc.
- Secteur
- Healthcare
- Industrie
- Biotechnology
- Bourse
- NASDAQ
- Capitalisation
- $1.6B
- Employés
- 170
- PDG
- Ian F. Smith
- Site web
- https://www.stoketherapeutics.com
- Marché
- BEAMDSGNIONSPASGPRQRSLN
Stoke Therapeutics, Inc. is an emerging biopharmaceutical company dedicated to developing innovative antisense oligonucleotide (ASO) therapies. Its primary focus is to target and address the fundamental causes of severe genetic disorders, particularly within the United States. The company employs its exclusive Targeted Augmentation of Nuclear Gene Output (TANGO) platform to engineer ASOs that precisely enhance protein expression. Stoke's most advanced candidate, STK-001, is currently progressing through Phase I/IIa clinical trials for Dravet syndrome, a severe and debilitating genetic epilepsy. Additionally, STK-002 is in the preclinical development stage for treating autosomal dominant optic atrophy. The company has also established a licensing and collaborative agreement with Acadia Pharmaceuticals Inc. to identify, develop, and market new RNA-based medicines for critical and rare genetic neurodevelopmental conditions impacting the central nervous system. Formerly known as ASOthera Pharmaceuticals, Inc., the company rebranded to Stoke Therapeutics, Inc. in May 2016. Founded in 2014, Stoke Therapeutics, Inc. maintains its headquarters in Bedford, Massachusetts.
Price (1 year)
Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.
VENTE TOTALE: 12 567 titres (~402 234,48 $ US)
- Insiders
- Kaye Edward M. MD
- Total bought
-
—
Avg buy (VWAP, 90d window) —
- Total sold
-
$164,318
Avg sell (VWAP, 90d window) $29.50 vs last close —
Total sold sums Form 4 code S in this window. Codes F, M, A and G are left out.
$131,070 of that total is under a Rule 10b5-1 plan. It is shown here and left out of the score.
- Last activity
- 2026-08-18
- Last synced
-
2026-08-25 17:08:49
Sign in to request a sync of this company's price history and timing levels.
Insider holdings as a share of total assets aren't available for this company.
Avg buy and avg sell are volume-weighted prices (sum of shares × price, divided by shares) for Form 4 rows in this 90-day window that report both figures. A comparison with last close is market context for that average, not advice.
Recent Form 4
Filings in the 90-day window for this company. Value is shares × price from the filing. Research, not advice.
| Date | Person | Side | Shares | Price | Value | Form 4 |
|---|---|---|---|---|---|---|
| 2026-10-02 | Allan Jonathan | Sell · S · 10b5-1 | 627 | $26.33 | $16,509 | Form 4 |
| 2026-10-01 | Ticho Barry | Sell · S · 10b5-1 | 1,051 | $26.16 | $27,494 | Form 4 |
| 2026-09-01 | Ticho Barry | Sell · S · 10b5-1 | 1,600 | $31.06 | $49,691 | Form 4 |
| 2026-08-18 | Allan Jonathan | Sell · S | 145 | $32.47 | $4,708 | Form 4 |
| 2026-08-18 | Kaye Edward M. MD | Sell · S | 637 | $32.47 | $20,682 | Form 4 |
| 2026-08-18 | Ticho Barry | Sell · S | 242 | $32.47 | $7,857 | Form 4 |
| 2026-08-03 | Ticho Barry | Sell · S · 10b5-1 | 1,269 | $29.45 | $37,377 | Form 4 |
Sales marked 10b5-1 are scheduled in advance and don't count toward the Quorum score. Les ventes marquées 10b5-1 sont planifiées à l'avance et ne pèsent pas dans le score Quorum.
Congressional trades
STOCK Act disclosures (90-day window)
Amounts are STOCK Act brackets as disclosed. Quorum does not turn a bracket into an exact price or a midpoint.
No STOCK Act disclosures for this company in this window.
Signal
Neutral signalScored 2026-08-26 Drivers: fundamentals. Moteurs : fondamentaux.
STOK presents a compelling event-driven setup anchored by strong Phase III EMPEROR trial enrollment momentum and significant institutional accumulation (Bank of America +163.4%), supported by a robust balance sheet and…
The first sentence of the analysis written for STOK on 2026-08-26 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Factor checklist — research, not advice
A check leans with a bullish reading. A cross leans against it. A dash is unavailable or mixed.
- Insider Pulls against a bullish reading. Selling cluster — sale value, no purchase value
- Congress Unavailable or mixed. No purchase disclosures in the stored window
- Narrative Unavailable or mixed. Stored narrative reading is in the neutral band
- Timing Unavailable or mixed. No stored price series
- Financial indicators Unavailable or mixed. Current ratio 5.28 · operating margin -11% — readings disagree
Market snapshot
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 100.0% | 100.0% | 100.0% | 100.0% | 0.0% | |
| Ebit Margin | -3.7% | -243.4% | -1192.5% | -814.7% | 0.0% | |
| Ebitda Margin | -2.8% | -237.5% | -1164.4% | -802.3% | 0.0% | |
| Operating Profit Margin | -11.2% | -277.3% | -1307.2% | -841.2% | 0.0% | |
| Pretax Profit Margin | -3.7% | -243.4% | -1192.5% | -814.7% | 0.0% | |
| Continuous Operations Profit Margin | -3.7% | -243.4% | -1192.5% | -814.7% | 0.0% | |
| Net Profit Margin | -3.7% | -243.4% | -1192.5% | -814.7% | 0.0% | |
| Bottom Line Profit Margin | -3.7% | -243.4% | -1192.5% | -814.7% | 0.0% | |
| Current Ratio | 5.282 | 5.811 | 6.987 | 7.774 | 13.374 | |
| Quick Ratio | 5.282 | 5.811 | 6.987 | 7.774 | 13.374 | |
| Solvency Ratio | -0.078 | -2.041 | -1.486 | -1.397 | -4.023 | |
| Cash Ratio | 1.455 | 3.195 | 6.212 | 3.617 | 8.454 | |
| Price To Earnings Ratio | -264.500 | -6.685 | -2.210 | -3.550 | -10.252 | |
| Price To Earnings Growth Ratio | 2.852 | 0.218 | 0.261 | -0.319 | -0.205 | |
| Forward Price To Earnings Growth Ratio | 2.852 | 0.218 | 0.261 | -0.319 | -0.205 | |
| Price To Earnings Diluted Ratio | -264.500 | -6.685 | -2.210 | -3.550 | -10.252 | |
| Price To Earnings Diluted Growth Ratio | 2.852 | 0.218 | 0.261 | -0.319 | -0.205 | |
| Price To Book Ratio | 5.333 | 2.601 | 1.450 | 1.942 | 4.047 | |
| Price To Sales Ratio | 10.192 | 16.296 | 26.357 | 28.942 | 0.000 | |
| Price To Free Cash Flow Ratio | 41.848 | -6.843 | -2.799 | -10.021 | -12.941 | |
| Price To Operating Cash Flow Ratio | 41.233 | -6.859 | -2.855 | -11.267 | -13.173 | |
| Debt To Assets Ratio | 0.007 | 0.018 | 0.009 | 0.009 | 0.021 | |
| Debt To Equity Ratio | 0.009 | 0.021 | 0.013 | 0.013 | 0.023 | |
| Debt To Capital Ratio | 0.008 | 0.020 | 0.013 | 0.013 | 0.023 | |
| Long Term Debt To Capital Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Financial Leverage Ratio | 1.187 | 1.186 | 1.431 | 1.385 | 1.097 | |
| Working Capital Turnover Ratio | 0.837 | 0.194 | 0.044 | 0.058 | 0.000 | |
| Operating Cash Flow Ratio | 0.788 | -2.168 | -2.630 | -1.015 | -3.904 | |
| Operating Cash Flow Sales Ratio | 0.247 | -2.376 | -9.233 | -2.569 | 0.000 | |
| Free Cash Flow Operating Cash Flow Ratio | 0.985 | 1.002 | 1.020 | 1.124 | 1.018 | |
| Debt Service Coverage Ratio | -568.333 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Interest Coverage Ratio | -2,287.778 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Operating Cash Flow Coverage Ratio | 15.160 | -18.193 | -39.315 | -13.508 | -13.278 | |
| Capital Expenditure Coverage Ratio | 68.037 | -427.837 | -50.165 | -8.043 | -55.756 | |
| Dividend Paid And Capex Coverage Ratio | 68.037 | -427.837 | -50.165 | -8.043 | -55.756 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | -351.594 | -5.443 | -0.411 | -2.490 | -8.741 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 100.0% | 0.0% | ▲20.0% |
| Ebit Margin | -3.7% | ▲239.7% | ▲447.1% |
| Ebitda Margin | -2.8% | ▲234.7% | ▲438.6% |
| Operating Profit Margin | -11.2% | ▲266.2% | ▲476.2% |
| Pretax Profit Margin | -3.7% | ▲239.7% | ▲447.1% |
| Continuous Operations Profit Margin | -3.7% | ▲239.7% | ▲447.1% |
| Net Profit Margin | -3.7% | ▲239.7% | ▲447.1% |
| Bottom Line Profit Margin | -3.7% | ▲239.7% | ▲447.1% |
| Current Ratio | 5.282 | ▼-0.529 | ▼-2.564 |
| Quick Ratio | 5.282 | ▼-0.529 | ▼-2.564 |
| Solvency Ratio | -0.077 | ▲1.963 | ▲1.727 |
| Cash Ratio | 1.455 | ▼-1.740 | ▼-3.131 |
| Price To Earnings Ratio | -264.500 | ▼-257.815 | ▼-207.061 |
| Price To Earnings Growth Ratio | 2.853 | ▲2.635 | ▲2.291 |
| Forward Price To Earnings Growth Ratio | 2.853 | ▲2.635 | ▲2.291 |
| Price To Earnings Diluted Ratio | -264.500 | ▼-257.815 | ▼-207.061 |
| Price To Earnings Diluted Growth Ratio | 2.853 | ▲2.635 | ▲2.291 |
| Price To Book Ratio | 5.333 | ▲2.732 | ▲2.258 |
| Price To Sales Ratio | 10.192 | ▼-6.104 | ▼-6.165 |
| Price To Free Cash Flow Ratio | 41.848 | ▲48.691 | ▲39.999 |
| Price To Operating Cash Flow Ratio | 41.233 | ▲48.092 | ▲39.817 |
| Debt To Assets Ratio | 0.007 | ▼-0.010 | ▼-0.006 |
| Debt To Equity Ratio | 0.009 | ▼-0.012 | ▼-0.007 |
| Debt To Capital Ratio | 0.009 | ▼-0.012 | ▼-0.007 |
| Long Term Debt To Capital Ratio | 0.000 | 0.000 | 0.000 |
| Financial Leverage Ratio | 1.187 | ▲0.002 | ▼-0.070 |
| Working Capital Turnover Ratio | 0.837 | ▲0.643 | ▲0.611 |
| Operating Cash Flow Ratio | 0.788 | ▲2.956 | ▲2.574 |
| Operating Cash Flow Sales Ratio | 0.247 | ▲2.623 | ▲3.033 |
| Free Cash Flow Operating Cash Flow Ratio | 0.985 | ▼-0.017 | ▼-0.045 |
| Debt Service Coverage Ratio | -568.333 | ▼-568.333 | ▼-454.667 |
| Interest Coverage Ratio | -2287.778 | ▼-2287.778 | ▼-1830.222 |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | 0.000 |
| Operating Cash Flow Coverage Ratio | 15.160 | ▲33.352 | ▲28.986 |
| Capital Expenditure Coverage Ratio | 68.037 | ▲495.875 | ▲162.790 |
| Dividend Paid And Capex Coverage Ratio | 68.037 | ▲495.875 | ▲162.790 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | -351.594 | ▼-346.151 | ▼-277.858 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $1.88B | $595.7M | $231.4M | $359.0M | $881.4M | |
| Enterprise value | $1.80B | $472.5M | $42.0M | $247.8M | $741.5M | |
| EV / Sales | 9.75x | 12.93x | 4.79x | 19.98x | 0.00x | |
| EV / Op. cash flow | 39.45x | -5.44x | -0.52x | -7.78x | -11.08x | |
| EV / Free cash flow | 40.04x | -5.43x | -0.51x | -6.92x | -10.89x | |
| EV / EBITDA | -351.59x | -5.44x | -0.41x | -2.49x | -8.74x | |
| Net debt / EBITDA | 15.88x | 1.42x | 1.85x | 1.12x | 1.65x | |
| Current ratio | 5.28x | 5.81x | 6.99x | 7.77x | 13.37x | |
| Income quality | -6.62x | 0.98x | 0.77x | 0.32x | 0.78x | |
| Graham net-net | $4 | $3 | $3 | $4 | $5 | |
| Tax burden | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| Interest burden | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| Working capital | $247.8M | $192.7M | $184.5M | $212.7M | $212.1M | |
| Invested capital | $254.1M | $201.0M | $197.0M | $224.1M | $221.2M | |
| Return on assets | -1.6% | -32.8% | -45.9% | -39.5% | -35.9% | |
| Operating ROA | -6.0% | -40.6% | -47.4% | -42.2% | -32.1% | |
| Return on tangible assets | -1.6% | -32.8% | -45.9% | -39.5% | -35.9% | |
| Return on equity | -2.0% | -38.9% | -65.6% | -54.7% | -39.4% | |
| Return on invested capital | -5.7% | -43.4% | -57.5% | -46.0% | -38.6% | |
| Return on capital employed | -5.7% | -43.8% | -58.1% | -46.4% | -38.8% | |
| Earnings yield | -0.4% | -14.9% | -45.2% | -28.2% | -9.7% | |
| Free cash flow yield | 2.4% | -14.6% | -35.7% | -10.0% | -7.7% | |
| Capex / Op. cash flow | 1.5% | -0.2% | -2.0% | -12.4% | -1.8% | |
| Capex / Depreciation | 37.9% | 9.3% | 65.5% | 256.3% | 123.2% | |
| Capex / Sales | 0.4% | 0.6% | 18.4% | 31.9% | 0.0% | |
| SG&A / Sales | 36.4% | 133.5% | 470.6% | 313.8% | 0.0% | |
| R&D / Sales | 74.8% | 243.8% | 936.6% | 627.5% | 0.0% | |
| Stock comp / Sales | 17.5% | 75.1% | 287.7% | 184.2% | 0.0% | |
| Intangibles / Total assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Days sales outstanding | 16d | 7d | 3d | 17d | 0d | |
| Days payables outstanding | 0d | 0d | 0d | 0d | 0d | |
| Operating cycle | 16d | 7d | 3d | 17d | 0d | |
| Cash conversion cycle | 16d | 7d | 3d | 17d | 0d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Change over 5 years
Employee count
Peer market caps
Recent news
- 2026-08-20 Bank of America Corp DE Buys 336,931 Shares of Stoke Therapeutics, Inc. $STOK Bank of America Corp DE lifted its stake in shares of Stoke Therapeutics, Inc. (NASDAQ: STOK) by 163.4% in the first quarter, according to the company in its most recent filing with the SEC. The fund owned 543,095 shares of the company''s stock after buying an additional 336,931 shares during the quarter. Bank
- 2026-08-18 Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body''s potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. The Company today announced that, effective on August 17, 2026, it granted stock options to purchase an aggregate of 70,950 shares of common stock to seven.
- 2026-08-17 Stoke Therapeutics'' Dravet Trial Tops Enrollment Target With Zero Dropouts Stoke Therapeutics NASDAQ: STOK said its Phase III EMPEROR study of zorevunersen for Dravet syndrome has enrolled 162 patients, exceeding its target enrollment of 150, with no patient discontinuations reported to date.
- 2026-08-05 Dimensional Fund Advisors LP Buys 162,797 Shares of Stoke Therapeutics, Inc. $STOK Dimensional Fund Advisors LP grew its position in Stoke Therapeutics, Inc. (NASDAQ: STOK) by 19.7% in the first quarter, according to its most recent filing with the SEC. The fund owned 989,936 shares of the company''s stock after acquiring an additional 162,797 shares during the period. Dimensional Fund Advisors LP owned 1.59% of
- 2026-08-05 Stoke Therapeutics Q2 Earnings Call Highlights Stoke Therapeutics (NASDAQ: STOK) said its Phase III EMPEROR study of zorevunersen in patients with Dravet syndrome remains on track for a data readout in the third quarter of 2027, following completion of enrollment ahead of the company''s planned rolling new drug application submission. The global, double-blind, sham-controlled study enrolled 162 patients in 10 months, exceeding
- 2026-08-04 These Analysts Revise Their Forecasts On Stoke Therapeutics After Q2 Results Stoke Therapeutics Inc (NASDAQ:STOK) on Monday posted mixed results for the second quarter.
- 2026-08-04 Stoke Therapeutics, Inc. (STOK) Q2 2026 Earnings Call Transcript Stoke Therapeutics, Inc. (STOK) Q2 2026 Earnings Call Transcript
- 2026-08-03 Stoke Therapeutics, Inc. (STOK) Reports Q2 Loss, Tops Revenue Estimates Stoke Therapeutics, Inc. (STOK) came out with a quarterly loss of $0.93 per share versus the Zacks Consensus Estimate of a loss of $0.82. This compares to a loss of $0.4 per share a year ago.
- 2026-08-03 Stoke Therapeutics Q2 Earnings Call Highlights Stoke Therapeutics NASDAQ: STOK said its Phase III EMPEROR study of zorevunersen in patients with Dravet syndrome remains on track for a data readout in the third quarter of 2027, following completion of enrollment ahead of the company''s planned rolling new drug application submission.
- 2026-08-03 Stoke Therapeutics Announces Second Quarter 2026 Financial Results and Provides Business Updates BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body''s potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. The Company today reported financial results for the second quarter ended June 30, 2026, and provided business updates including progress of the global Pha.